Convergent or Linear? A Challenging Question in Carbocyclic Nucleoside Chemistry

Olaf R. Ludek; Victor E. Marquez

doi:10.1055/s-2007-990847

PAPER

Convergent or Linear? A Challenging Question in Carbocyclic Nucleoside Chemistry

Olaf R. Ludek, Victor E. Marquez*
Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, 376 Boyles Street, Frederick, MD 21702, USA
Fax: +1(301)8466033; e-Mail: marquezv@mail.nih.gov;

Abstract

All articles of this category

Abstract

North-methanocarbathymidine (N-MCT) is a carbocyclic nucleoside analogue with potent anti-HSV and KSHV activity. The critical step in the synthesis of N-MCT and other carbocyclic nucleoside analogues is the introduction of the nucleobase into the carbocyclic moiety. For this, convergent and linear strategies were compared side by side. In the convergent approach, the base was coupled to the carbocyclic moiety by either a Mitsunobu reaction or by displacement of a mesylate. This strategy leads to the formation of various amounts of the O ²-regioisomer, depending on the applied procedure. Additionally, by-products of the Mitsunobu reaction have to be separated from the coupling products. Although lengthier, the linear strategy leads selectively to the target compound N-MCT with overall yields comparable to the convergent approaches, making this strategy more compatible for future large-scale syntheses.

Key words

medicinal chemistry - nucleosides - carbocycles - Mitsunobu reaction - regioselectivity

Full Text

References

For reviews on the synthesis of carbocyclic nucleosides, see:

<A NAME="RM03807SS-1A">1a</A> Borthwick AD. Biggadike K. Tetrahedron 1992, 48: 571

<A NAME="RM03807SS-1B">1b</A> Agrofoglio L. Suhas E. Farese A. Condom R. Challand SR. Earl RA. Guedj R. Tetrahedron 1994, 50: 10611

<A NAME="RM03807SS-1C">1c</A> Crimmins MT. Tetrahedron 1998, 54: 9229

<A NAME="RM03807SS-1D">1d</A> Zhu XF. Nucleosides, Nucleotides Nucleic Acids 2000, 19: 651

For selected reviews on biological properties of nucleoside analogues, see:

<A NAME="RM03807SS-2A">2a</A> Nucleosides and Nucleotides as Antitumor and Antiviral Agents Chu CK. Baker DC. Plenum Press; New York: 1993.

<A NAME="RM03807SS-2B">2b</A> De Clercq E. Ann. N. Y. Acad. Sci. 1994, 724: 438

<A NAME="RM03807SS-2C">2c</A> Nair V. Jahnke TS. Antimicrob. Agents Chemother. 1995, 39: 1017

<A NAME="RM03807SS-2D">2d</A> Wilson LJ. Hager MW. El-Kattan YA. Liotta DC. Synthesis 1995, 1465

<A NAME="RM03807SS-2E">2e</A> Chu CK. Nucleic Acids Symp. Ser. 1996, 35: 1

<A NAME="RM03807SS-2F">2f</A> Marquez VE. In Advances in Antiviral Drug Design Vol. 2: De Clercq E. JAI Press; Greenwich: 1996. p.89

<A NAME="RM03807SS-2G">2g</A> Mitsuya H. In Anti-HIV Nucleosides: Past, Present and Future Landes; Texas: 1997.

<A NAME="RM03807SS-2H">2h</A> Pan S. Amankulor NM. Zhao K. Tetrahedron 1998, 54: 6587

<A NAME="RM03807SS-2I">2i</A> Agrogoglio LA. Challand SR. In Acyclic, Carbocyclic and l -Nucleosides Kluwer Academic Publishers; Dordrecht: 1998.

<A NAME="RM03807SS-2J">2j</A> Simons C. In Nucleoside Mimetics: Their Chemistry and Biological Properties Gordon and Breach Science Publishers; New York: 2001.

<A NAME="RM03807SS-3">3</A> Marquez VE. Hughes SH. Sei S. Agbaria R. Antiviral Res. 2006, 71: 268

<A NAME="RM03807SS-4A">4a</A> Rodriguez JB. Marquez VE. Nicklaus MC. Barchi JJ. Tetrahedron Lett. 1993, 34: 6233

<A NAME="RM03807SS-4B">4b</A> Altmann KH. Kesselring R. Francotte E. Rihs G. Tetrahedron Lett. 1994, 35: 2331

<A NAME="RM03807SS-4C">4c</A> Rodriguez JB. Marquez VE. Nicklaus MC. Mitsuya H. Barchi JJ. J. Med. Chem. 1994, 37: 3389

<A NAME="RM03807SS-5">5</A> Altona C. Sundaralingam M. J. Am. Chem. Soc. 1972, 94: 8205

<A NAME="RM03807SS-6A">6a</A> Marquez VE. Ezzitouni A. Russ P. Siddiqui MA. Ford H. Feldman RJ. Mitsuja H. George C. Barchi JJ. J. Am. Chem. Soc. 1998, 120: 2780

<A NAME="RM03807SS-6B">6b</A> Marquez VE. Russ P. Alonso R. Siddiqui MA. Hernandez S. George C. Nicklaus MC. Dai F. Ford H. Helv. Chim. Acta 1999, 82: 2119

<A NAME="RM03807SS-6C">6c</A> Kim HS. Ravi RG. Marquez VE. Maddileti S. Wihlborg A.-K. Erlinge D. Malmsjö M. Boyer JL. Harden TK. Jacobson KA. J. Med. Chem. 2002, 45: 208

<A NAME="RM03807SS-6D">6d</A> Marquez VE. Ben-Kasus T. Barchi JJ. Green KM. Nicklaus MC. Agbaria R. J. Am. Chem. Soc. 2004, 126: 543

<A NAME="RM03807SS-6E">6e</A> Marquez VE. Choi Y. Comin MJ. Russ P. George C. Huleihel M. Ben-Kasus T. Agbaria R. J. Am. Chem. Soc. 2005, 127: 15145

<A NAME="RM03807SS-6F">6f</A> Comin MJ. Agbaria R. Ben-Kasus T. Huleihel M. Liao C. Sun G. Nicklaus MC. Deschamps JR. Parrish DA. Marquez VE. J. Am. Chem. Soc. 2007, 129: 6216

<A NAME="RM03807SS-7A">7a</A> Marquez VE. Siddiqui MA. Ezzitouni A. Russ P. Wang J. Wagner RW. Matteucci MD. J. Med. Chem. 1996, 39: 3739

<A NAME="RM03807SS-7B">7b</A> Ezzitouni A. Marquez VE. J. Chem. Soc., Perkin Trans. 1 1997, 1073

<A NAME="RM03807SS-7C">7c</A> Russ P. Schelling P. Scapozza L. Folkers G. De Clercq E. Marquez VE. J. Med. Chem. 2003, 46: 5045

<A NAME="RM03807SS-8A">8a</A> Zalah L. Huleihel M. Manor E. Konson A. Ford H. Marquez VE. Johns DG. Agbaria R. Antiviral Res. 2002, 55: 63

<A NAME="RM03807SS-8B">8b</A> Huleihel M. Talishanisky M. Ford H. Marquez VE. Kelley JA. Johns DG. Agbaria R. Int. J. Antimicrob. Agents 2005, 25: 427

<A NAME="RM03807SS-9">9</A> Zhu W. Burnett A. Dorjsuren D. Roberts PE. Huleihel M. Shoemaker RH. Marquez VE. Agbaria R. Sei S. Antimicrob. Agents Chemother. 2005, 49: 4965

<A NAME="RM03807SS-10">10</A> Boyer PL. Julias JG. Marquez VE. Hughes SH. J. Mol. Biol. 2005, 345: 441

<A NAME="RM03807SS-11A">11a</A> Moon HR. Ford H. Marquez VE. Org. Lett. 2000, 2: 3793

<A NAME="RM03807SS-11B">11b</A> Yoshimura Y. Moon HR. Choi Y. Marquez VE. J. Org. Chem. 2002, 67: 5938

<A NAME="RM03807SS-12">12</A> Cruickshank KA. Jiricny J. Reese CB. Tetrahedron Lett. 1984, 25: 681

<A NAME="RM03807SS-13">13</A> . Zanilpa SA. Guzman A. Morgans DJ. Synth. Commun. 2001, 31: 3739

<A NAME="RM03807SS-14A">14a</A> Mitsunobu O. Synthesis 1981, 1

<A NAME="RM03807SS-14B">14b</A> Hughes DL. Org. React. 1993, 42: 335

<A NAME="RM03807SS-15A">15a</A> Jenny TF. Previsani N. Benner SA. Tetrahedron Lett. 1991, 32: 7029

<A NAME="RM03807SS-15B">15b</A> Jenny TF. Horlacher J. Previsani N. Benner SA. Helv. Chim. Acta 1992, 75: 1944

<A NAME="RM03807SS-16A">16a</A> Choo H. Chong Y. Chu CK. Org. Lett. 2001, 3: 1471

<A NAME="RM03807SS-16B">16b</A> Ludek OR. Meier C. Synlett 2006, 324

<A NAME="RM03807SS-17A">17a</A> Schmitt L. Caperelli CA. Nucleosides Nucleotides 1997, 16: 2165

<A NAME="RM03807SS-17B">17b</A> Ludek OR. Meier C. Eur. J. Org. Chem. 2006, 941

<A NAME="RM03807SS-18A">18a</A> Bonnal C. Chavis C. Lucas M. J. Chem. Soc., Perkin Trans. 1 1994, 1401

<A NAME="RM03807SS-18B">18b</A> Ludek OR. Meier C. Synlett 2005, 3145

<A NAME="RM03807SS-19">19</A> Borthwick AD. Crame AJ. Exall AM. Weingarten GG. Mahmoudian M. Tetrahedron Lett. 1995, 36: 6929

<A NAME="RM03807SS-20A">20a</A> Ludek OR. Meier C. Synthesis 2003, 2101

<A NAME="RM03807SS-20B">20b</A> Ludek OR. Krämer T. Balzarini J. Meier C. Synthesis 2006, 1313

For reviews on atom economy, see:

<A NAME="RM03807SS-21A">21a</A> Trost BM. Angew. Chem., Int. Ed. Engl. 1995, 34: 259

<A NAME="RM03807SS-21B">21b</A> Trost BM. Acc. Chem. Res. 2002, 35: 695

In recent years many strategies were developed to encounter these drawbacks, including solid-phase chemistry and modified reagents that extract into aqueous media. For reviews on simplified workup procedures, see:

<A NAME="RM03807SS-22A">22a</A> Dembinski R. Eur. J. Org. Chem. 2004, 2763

<A NAME="RM03807SS-22B">22b</A> Dandapani S. Curran DP. Chem. Eur. J. 2004, 10: 3130

<A NAME="RM03807SS-23A">23a</A> Harnden MR. Jarvest RL. Bacon TH. Boyd MR. J. Med. Chem. 1987, 30: 1636

<A NAME="RM03807SS-23B">23b</A> Choudary BM. Geen GR. Kincey PM. Parratt MJ. Nucleosides Nucleotides 1996, 15: 981

<A NAME="RM03807SS-24A">24a</A> Slusarchyk WA. Young MG. Bisacchi GS. Hockstein RR. Zahler R. Tetrahedron Lett. 1989, 30: 6453

<A NAME="RM03807SS-24B">24b</A> Borcherding DR. Peet NP. Munson HR. Zhang H. Hoffman PF. Bowlin TL. Edwards CK. J. Med. Chem. 1996, 39: 2615

<A NAME="RM03807SS-25A">25a</A> Baumgartner H. Marschner C. Pucher R. Griengl H. Tetrahedron Lett. 1991, 32: 611

<A NAME="RM03807SS-25B">25b</A> Ueno Y. Karino N. Matsuda A. Bioconjugate Chem. 2000, 11: 933

<A NAME="RM03807SS-26A">26a</A> Pelissier H. Rodriguez J. Vollhardt KPC. Chem. Eur. J. 1999, 5: 3549

<A NAME="RM03807SS-26B">26b</A> Paryzek Z. Tabaczka B. Org. Prep. Proced. Int. 2001, 33: 400

<A NAME="RM03807SS-26C">26c</A> Howarth NM. Wakelin LPG. Walker DM. Tetrahedron Lett. 2003, 44: 695

<A NAME="RM03807SS-26D">26d</A> Young JEP. Horenstein NA. Tetrahedron Lett. 2004, 45: 9505

<A NAME="RM03807SS-27A">27a</A> Zook HD. Gumby WL. J. Am. Chem. Soc. 1960, 82: 1386

<A NAME="RM03807SS-27B">27b</A> Cacciapaglia R. Mandolini V. J. Org. Chem. 1988, 53: 2579

The ammonium salts were prepared prior to the reaction by adding stoichiometric amounts of either tetramethylam-monium or tetrabutylammonium hydroxide to the BOM-protected heterocycle 4 in water. The obtained solutions were lyophilized and the crude salts were used without any further purification.

<A NAME="RM03807SS-29">29</A> Reichardt C. Solvents and Solvent Effects in Organic Chemistry 2nd ed.: VCH; Weinheim: 1988.

<A NAME="RM03807SS-30">30</A> Bodenteich M. Griengl H. Tetrahedron Lett. 1987, 44: 5311